Analyst Charles Rhyee from TD Cowen maintained a Buy rating on GoodRx Holdings and keeping the price target at $7.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charles Rhyee has given his Buy rating due to a combination of factors that suggest potential growth for GoodRx Holdings. One significant element is the company’s partnership with Novo Nordisk (NVO), which is expected to enhance GoodRx’s Managed Solutions revenue. This partnership is particularly promising given the high level of patient activity on GoodRx’s platform related to GLP-1 medications, indicating strong consumer interest and potential revenue growth.
Additionally, Charles Rhyee notes that GoodRx’s stock has been somewhat de-risked following the management’s adjustment of their 2025 guidance due to RAD store closures and lower ISP contributions. Furthermore, there is potential for GoodRx to engage in a partnership with government efforts to lower drug pricing, which could provide additional opportunities for growth. These factors, combined with the company’s strategic focus on new growth metrics, contribute to the positive outlook and Buy rating.
In another report released on October 2, TR | OpenAI – 4o also upgraded the stock to a Buy with a $5.50 price target.